Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Short term Debt: 2021-2024

  • Abivax's Short term Debt rose 19.49% to $48.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $48.0 million, marking a year-over-year increase of 19.49%. This contributed to the annual value of $48.0 million for FY2024, which is 19.49% up from last year.
  • As of Q4 2024, Abivax's Short term Debt stood at $48.0 million, which was up 19.49% from $40.2 million recorded in Q4 2023.
  • Abivax's Short term Debt's 5-year high stood at $48.0 million during Q4 2024, with a 5-year trough of $13.0 million in Q4 2021.
  • Moreover, its 3-year median value for Short term Debt was $40.2 million (2023), whereas its average is $40.8 million.
  • Data for Abivax's Short term Debt shows a peak YoY surged of 163.78% (in 2022) over the last 5 years.
  • Quarterly analysis of 4 years shows Abivax's Short term Debt stood at $13.0 million in 2021, then soared by 163.78% to $34.2 million in 2022, then rose by 17.38% to $40.2 million in 2023, then increased by 19.49% to $48.0 million in 2024.
  • Its Short term Debt stands at $48.0 million for Q4 2024, versus $40.2 million for Q4 2023 and $34.2 million for Q4 2022.